"Product (company, year of approval, disease)",Revenue in million U.S. dollars
"Stelara (Janssen, 2015, CD)",399.5
"Xeljanz (Pfizer, 2017, UC)",101.0
"Vercimon (ChemoCentryx, 2019, CD)",93.6
"Kappaproct (InDeX Pharmaceuticals, 2014, UC)*",47.0
